Population Phamacokinetic-Pharmacodynamic Assessment of Cardiac Safety Endpoints for CF-301, a First-In-Class Antibacterial Lysin Presented at ASM Microbe 2017, June 3, 2017
Inflammatory Markers in a Phase 1 Placebo Controlled Dose Escalating Study of Intravenous Doses of CF-301 in Human Subjects Presented at ASM Microbe 2017, June 2, 2017
Low Propensity of Resistance Development In Vitro in Staphylococcus aureus with Lysin CF-301 Presented at ASM Microbe 2017, June 2, 2017
Quality Control Studies of CF-301 versus Staphylococcus aureus ATCC 29213 and Enterococcus faecalis ATCC 29212 Presented at ASM Microbe 2017, June 2, 2017
Development of an Antimicrobial Susceptibility Test (AST) for the Antistaphylococcal Lysin CF-301 Presented at 27th ECCMID, April 22, 2017
Long Term Immunology Results of a Phase 1 Placebo Controlled Dose Escalating Study to Examine the Safety of CF-301 in Human Volunteers Presented at 27th ECCMID, April 22, 2017
Staphylococcus aureus Resistance to Lysin CF-301 Does Not Arise in Human Serum Oral Presentation at ASM Microbe 2016, June 20
Post-Antibiotic Effects of Lysin CF-301 Against Staphylococcus aureus in Human Serum Oral Presentation at ASM Microbe 2016, June 20
PK-PD Driver of Efficacy for CF-301, a Novel Anti-Staphylococcal Lysin: Implications for Human Target Dose Presented at ASM Microbe 2016, June 18
